Legend Biotech (NASDAQ:LEGN) just reported results for the first quarter of 2024.
- Legend Biotech reported earnings per share of -16 cents. This was above the analyst estimate for EPS of -34 cents.
- The company reported revenue of $93.99 million.
- This was 38.42% worse than the analyst estimate for revenue of $152.63 million.